| Prev Close | 2.30 |
| Open | 2.39 |
| Day Low/High | 2.14 / 2.41 |
| 52 Wk Low/High | 3.34 / 8.79 |
| Volume | 373.02K |
| Avg Volume | 183.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 20.07M |
| Market Cap | 41.13M |
| EPS | -1.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Imprimis Pharmaceuticals Patent-Pending Dropless And LessDrops Formulations Exceed One Million Patient Eyes Milestone
Medications dispensed from Imprimis' FDA-registered outsourcing facility have provided patients and physicians with innovative high-quality solutions for ocular surgery recovery
Imprimis Pharmaceuticals Sells Pennsylvania Facility And Sinus Assets
Imprimis to focus resources on rapidly-growing core ophthalmology business
Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer And Director
Mr. Brynjelsen to lead development of Eton's proprietary sterile injectable branded product candidates
Eton Pharmaceuticals Announces $20 Million Series A Financing
Proceeds to support the development of Eton's proprietary corticotropin product candidate, Peyronie's Disease product candidate and other sterile injectable product candidates
Imprimis Pharmaceuticals And SightLife Surgical Sign Agreement For National Launch Of Serum Tears™
Imprimis begins roll-out of dry eye disease formulary with innovative autologous serum eye drop program
Imprimis Pharmaceuticals And Precision Lens Sign Agreement To Expand Imprimis' Ophthalmic Portfolio Market Opportunity In The U.S. Midwest
Largest distributor of ophthalmic products in the Midwest to expand Imprimis' ability to serve strategic accounts and accelerate growth
Imprimis Pharmaceuticals Acquires Exclusive License To Patented Ophthalmic Formulation For Dry Eye Disease
Formulation Expected to be a Cornerstone of Imprimis' New Dry Eye Program
Peer-Reviewed Paper Demonstrates The Benefits Of Dropless Cataract Surgery®
Compliance, cost-savings and efficacy listed as key reasons to adopt Dropless Therapy®
Imprimis Pharmaceuticals Begins Dispensing From FDA-Registered 503B Outsourcing Facility
Improved efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio
EpiPen Price Relief Could Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
These 5 Under-$10 Stocks Are Set to Soar Higher
These under-$10 stocks look poised to break out and trade higher from current levels.
These 7 Stocks Under $10 Are Set to Soar Higher
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
3 Stocks Pushing The Drugs Industry Lower
TheStreet highlights 3 stocks pushing the Drugs industry lower today.
Biotech Sector Performance February 2014: Red Hot But...
An epic month of biotech stock performance ends with a significant sell off.
Imprimis Pharmaceuticals Innovates Back to Basics With Compounding
Few firms are positioned to take advantage of a custom Rx trend, but Imprimis has a helpful partner.
Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc.
Ratings Changes To Be Publicly Issued on 5/31/13
Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:
2 Biotech Stocks Under $10 to Watch
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
